Observational outcome results following a randomized controlled trial of early amino acid administration in preterm

Chris H P van den Akker1, Frans W J te Braake, Nynke Weisglas-Kuperus

  • 1*Pediatrics-Neonatology, Erasmus MC-Sophia Children's Hospital, Rotterdam †Pediatrics, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands.

Insights

Early amino acid administration improved long-term outcomes for premature boys, but not girls. Further research is needed on the observed lower mental development in girls receiving early amino acids.

Area of Science:

  • Neonatal Medicine
  • Developmental Pediatrics
  • Nutritional Science

Background:

  • Previous studies on amino acid administration in premature infants focused on short-term outcomes.
  • Long-term neurodevelopmental and anthropometric data are crucial for evaluating early nutritional interventions.

Purpose of the Study:

  • To assess the long-term effects of early amino acid administration on survival and neurodevelopment in premature infants.
  • To compare outcomes between infants receiving glucose versus glucose with amino acids from birth.

Main Methods:

  • A randomized controlled trial involving infants born before 32 weeks' gestation and weighing less than 1500g.
  • Infants received either glucose or glucose with amino acids from birth, with similar nutritional intake from day 3.
  • Neurodevelopmental outcomes and anthropometry were assessed at 2 years of corrected age.

Main Results:

  • No overall difference in survival without major disabilities between groups.
  • Premature boys showed significantly better outcomes with early amino acid administration (OR 6.2).
  • No differences in anthropometry; a subgroup of girls exhibited a lower mental developmental index.

Conclusions:

  • Early amino acid supplementation benefits neurodevelopment in premature boys but not girls.
  • The potential negative impact on girls' mental development warrants further investigation.
Abstract

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
240
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
557